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Abstract
Objective: Friedreich ataxia (FRDA) is an autosomal recessive ataxia resulting
from mutations in the frataxin gene (FXN). Such mutations, usually expanded
guanine–adenine–adenine (GAA) repeats, give rise to decreased levels of frataxin protein in both affected and unaffected tissues. The goal was to understand the relationship of frataxin levels in peripheral tissues to disease status.
Methods: Frataxin levels were measured in buccal cells and blood, and analyzed in relation to disease features. Site-directed mutant frataxin was also
transfected into human embryonic kidney cells to model results from specific
point mutations. Results: There was no evidence for change in frataxin levels
over time with repeated measures analysis, although linear regression analysis
of cross-sectional data predicted a small increase over decades. GAA repeat
length predicted frataxin levels in both tissues, and frataxin levels themselves
predicted neurological ratings (accounting for age). Compound heterozygous
patients for a GAA expansion and a point mutation in FXN generally had
lower levels of frataxin than those homozygous for the presence of two GAA
repeat expansions, though levels varied dramatically between tissues in some
compound heterozygotes for point mutations. The G130V mutation led to
decreased levels of frataxin in vitro as well as in vivo, while the R165C mutation produced normal immunoreactive levels of frataxin both in vitro and
in vivo. Start codon mutations led to low levels of frataxin in buccal cells but
preserved immunoreactive frataxin levels in blood. Interpretation: The present
data show that peripheral frataxin levels reflect disease features in FRDA, but
emphasize the need for interpretation of such levels in the context of specific
mutations.

Introduction
Friedreich ataxia (FRDA) is an autosomal recessive disorder associated with progressive ataxia, cardiomyopathy,

scoliosis, and diabetes.1,2 In 98% of individuals, FRDA is
caused by homozygous expanded guanine–adenine–
adenine (GAA) repeats in the frataxin gene (FXN), with
the other 2% of individuals being compound heterozygotes
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for a point mutation or, less commonly, a deletion3–9 in
one allele and expanded GAA repeat on the other. The
expanded GAA repeat decreases expression of the mitochondrial protein frataxin by disrupting mRNA transcription.1 Most pathogenic point mutations disrupt RNA
splicing, translation initiation, or protein folding of frataxin and result in minimal functional protein.3–8 Other
mutations (e.g., R165C, W155R, I154F, and G130V) are
not within the core of the protein, and could give rise to
dysfunctional frataxin that is present but less active.6,9
Thus, in all individuals, FRDA likely reflects loss of
functional frataxin. Reduced frataxin levels impair the
function of mitochondrial iron-sulfur-cluster-containing
enzymes and ability to produce ATP.10,11 Frataxindepleted cells have an increased sensitivity to oxidative
stress.10,11
At present, no treatment is approved for FRDA, but
multiple therapeutics in development may increase levels
of frataxin. Erythropoietin raises frataxin levels in
peripheral tissues by nontranscriptional means, but the
effect appears too small to produce significant effects.12
Selective histone deacetylase inhibition has been successful in vitro and in mice, and has increased levels of frataxin mRNA in a phase I trial.13,14 Interferon-c increases
frataxin levels in mice and in FRDA patient-derived
cells.15,16
Consequently, accurate assessments of frataxin are crucial in advancing therapeutic development in FRDA. As
the mutations in FXN are found in all cells, frataxin deficiency occurs both in affected and unaffected tissues.
Affected tissues such as cardiac and neuronal tissue are
difficult to sample, making assessment of frataxin levels in
peripheral tissues (e.g., blood, buccal cells) important in
monitoring the disease and the response to therapies.
Patients with FRDA have frataxin levels in peripheral tissues that range from 2% to 30% of control levels.7,9,17,18
These levels correlate with age of onset and inversely with
the length of the GAA repeat. In carriers, who do not
develop symptoms of FRDA, frataxin protein levels range
from 30% to 80% of control levels.7,9,17,18 The lack of
symptoms observed in carriers suggests that restoration of
frataxin levels in patients to those observed in carriers
may lead to substantial improvement in the course of the
disease. Fulfilling such a goal requires a detailed understanding of the measurement of frataxin in subjects. In
the present study we increased the sample size of our previous cohort,7 used repeated measures of subjects,
extended correlations in multiple tissues, and looked in
detail at results from compound heterozygotes for GAA
expansions and selected point mutations to examine the
utility of frataxin measurement in buccal cells and blood
cells.
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Methods
Patients
The protocol was approved by the Institutional Review
Boards of all sites. Informed consent was obtained from
each subject. Whole blood and buccal cell samples were
obtained from patients with FRDA in a longitudinal clinical natural history study at the Children’s Hospital of
Philadelphia, University of California–Los Angeles Medical Center, Emory University School of Medicine, University of Iowa, University of Florida, University of South
Florida, The Ohio State University and Sick Kids Hospital
(Toronto).19–21 Clinical information19–21 included the
Friedreich Ataxia Rating Scale (FARS) exam, individual
performance measures (timed 25-foot walk; nine-hole peg
test, low-contrast letter acuity) and performance measure
composites Z2 and Z3. The performance measure composites were derived as described from the nine-hole peg test
and timed 25 foot walk (Z2), with low contrast letter acuity added in the Z3 score.19,20 GAA repeat lengths were
available from clinical testing on blood samples, and the
correlation of GAA length with age of onset is 0.6.19–21
Carrier samples were available from siblings and parents
of FRDA subjects. Control samples included relatives not
carrying GAA repeats, step-siblings, and healthy volunteers unrelated to FRDA subjects.

Frataxin assay
Buccal cell and whole blood samples were obtained at
clinical visits from subjects and were prepared and
assayed for frataxin immunoreactivity by lateral flow
(“dipstick”) as described previously.7 We attempted to get
blood and buccal cells at the same visit. The lateral flow
assay has low coefficients of variation making it useful in
large cohorts.7

Western blot
Buccal or fibroblast cells were collected in extraction buffer (Abcam, Cambridge, MA) and mixed with sodium
dodecyl sulfate (SDS) sample buffer. Following extraction,
a sample (28 lg) of total protein was boiled for 5 min
and loaded onto 15% polyacrylamide gel. Following SDS
polyacrylamide gel electrophoresis (PAGE), proteins were
transferred to nitrocellulose, blocked with 3% dry milk,
and incubated with mouse anti-frataxin antibody (Abcam,
Cambridge, MA). Blots were then incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies and developed with enhanced
chemiluminescence (Pierce, Rockford, IL).
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Transfection of HEK cells and
immunocytochemical staining
The pcDNA3/FXN mutant constructs for FXNG130V,
FXNR165C, FXNI154F, were generated using the Stratagene
Quick-Change XLII Site-Directed Mutagenesis Kit (La Jolla, CA) with specific primers using human Frataxin1-210
as a template. The primers for these mutations were as
follows: 50 CAGTTTGACAGTTAAGACAACACTCCCAA
AGGAGACATC 30 (G130V); 50 CAGTCCAGTCATA
ACACTTAGGTCCACTGGATGG 30 (R165C); and 50
GATGGAGAAGATAGCCAGAATTGCTTGTTTGGCGT 30
(I154F). All mutations were verified by sequencing.
Coverslips were coated with 5 mg/mL poly-D-lysine and
seeded with human embryonic kidney (HEK)-293 cells,
maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and Penicillin/
Streptomycin. Once cells reach 70% confluency, HEK-293
cells were cotransfected with 3 lg pcDNA3/FXNG130V,
FXNR165C, FXNI154F, or FXNWildtype and 3 lg of mitoGFP
in a six-well plate. Twenty-four hours after transfection
cells were fixed with 4% Paraformaldehyde, permeablized
with 0.3% Triton, and blocked with 10% bovine serum
albumin. Mouse anti-Frataxin antibody (ab110328; Abcam,
Cambridge, MA) was then added and incubated overnight,
followed by Alexa Fluor 568 (Life technologies, Eugene,
OR) fluorescent second antibody the next day.
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(1 lg/mL, Abcam, Cambridge, MA) overnight at 4°C. On
the second day, 25 lL of protein G beads were added to
the samples and incubated at 4°C for 2 h. The samples
were then centrifuged at 500g for 5 min, and the beads
were washed four times with extraction buffer. A total of
50 lL of sample buffer for SDS-PAGE was then added, and
the mixture was boiled for 5 min. Beads were pelleted by
centrifugation, and a fixed volume of supernatant was
applied to a 15% polyacrylamide gel for SDS-PAGE.

Separation of components of whole blood
Briefly, whole blood was drawn into acid–citrate–dextrose
Vacutainer tubes, transferred to polypropylene tubes, and
centrifuged for 15 min at 129g with no brakes.22 The pellet
was saved as the red blood cell (RBC) fraction (though it
also included peripheral blood mononuclear cell (PBMC))
and the upper platelet-rich plasma layer was transferred to
a new tube and spun again at 329g with no brakes for
15 min. The platelets were contained in the pellet.

Statistical analysis

In order to address specific results arising in buccal and
blood cells, fibroblasts were prepared from skin biopsies from
patients with FRDA or controls. The biopsies from subjects
with FRDA included a patient with long GAA repeats (repeat
lengths of 901, 901), a patient with short GAA repeats (126,
520), and a patient with a G130V allele with a single
expanded GAA of 762 repeats on the other allele.

Initial data analysis was performed using STATA software
(v. 11.1; StataCorp LC) (College Station, TX) and SAS
(Cary, NC). Mean patient frataxin levels were expressed as
a percentage of average control levels derived from series of
control samples from the same assay. The mean age at collection for each patient was used in this study. For linear
regressions, models were created to predict frataxin levels
using age, sex, and shorter GAA repeat length as independent variables. In preliminary analyses, collection site was
also used as an independent variable. In addition, models
were created to assess the ability of frataxin level to predict
neurologic features using age and sex as independent variables along with buccal or blood frataxin protein level. Significance was determined based on P < 0.05.

Immunoprecipitation

Results

Fibroblasts

To identify the molecular weight of frataxin in blood (as
western blots are confounded by high levels of hemoglobin), samples of control and patient whole blood (400 lL)
were mixed with 1600 lL extraction buffer (Abcam, Cambridge, MA) with a protease inhibitor cocktail (1:500 dilution; Calbiochem, Darmstadt, Germany) and incubated on
ice for ≥10 min. Blood samples were then centrifuged at
16,000g for 10 min. The supernatant was transferred to a
new tube and incubated with 60 lL of protein G beads
(Invitrogen, Carlsbad, CA) at 4°C for 1 h to remove proteins that bind nonspecifically to the beads. The samples
were then centrifuged at 500g for 5 min and the supernatant was incubated with mouse anti-frataxin antibody

Patient clinical and demographic
information
The 521 FRDA patients were first characterized demographically (Table 1). There were no significant differences in mean age or sex between buccal and whole
blood assay subjects (data not shown).

Assessing the variability in frataxin
measurements
The short-term reproducibility of the frataxin assay previously was excellent for technical replicates, but had larger
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Table 1. Demographic features.
Shorter GAA
length

Sample

N

FRDA

521

Carriers
Controls

306
119

622  240
(41–1150)
–
–

Age, years (range)

Sex (%
female)

28.4  15.5 (3–78)

49.5%

47.8  12.8 (2–79)
38.1  14.9 (4–80)

58.0%
47.2%

GAA, guanine–adenine–adenine; FRDA, Friedreich ataxia.

variability in repeated sampling in buccal and whole
blood samples.7,14 In addition, previous regression analyses suggested that peripheral frataxin levels changed minimally over the course of a lifetime. To revisit these issues,
the variability in frataxin measurements was assessed in
repeated samplings over several years by examining the
relationship between the difference in frataxin level
between the first and second samplings and the interval
in time between samplings. There was no relationship
between the difference in frataxin levels and the interval
between measurements in buccal cells (R2 = 0.013,
P = 0.17) and whole blood (R2 = 0.0004, P = 0.81)
(Fig. 1A and B). There was also little-to-no correlation of
the difference in frataxin levels between measurements
with GAA repeat length (buccal: R2 = 0.0405, P = 0.016;
blood: R2 = 0.0003, P = 0.858) or age (buccal: R2 =
0.047, P = 0.009; blood: R2 = 0.0048, P = 0.422) in either
tissue. Although these models were statistically significant
in buccal cells, the low R2 values demonstrated a minimal
relationship identified only due to the large size of the
cohort. In contrast, the difference between the first and
second frataxin samplings was predicted by the first frataxin measurement from buccal cells (R2 = 0.47,
P < 0.001) and whole blood samples (R2 = 0.23,
P < 0.001) (Fig. 1C and D). The second measurement
significantly proceeded toward the mean frataxin level for
the cohort, showing that regression to the mean is the
dominant identifiable feature of sampling variability with
no evidence for biological changes in frataxin levels over
time.

Relationship of frataxin data to disease
features
As frataxin levels appear not to change over short periods
of time, mean levels from each subject were used to reexamine the relationship between frataxin levels and disease
features. In initial models, sex and collection site showed
no association with frataxin levels, and were omitted
from subsequent models (data not shown). Frataxin levels in buccal cells correlated with GAA repeat length on
the shorter allele (R2 = 0.19, P < 0.001) and with the
average age of collection from patients (R2 = 0.13,
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P < 0.001) (Fig. 2A and B). In addition, age of onset
correlated with blood and buccal frataxin level. Linear
regression models demonstrated that both GAA repeat
length on the shorter allele (regression coefficient
= 0.024  0.004, P < 0.001) and mean age at the time
of collection (regression coefficient = 0.21  0.06,
P = 0.001) independently predicted frataxin levels
(R2 = 0.22, P < 0.001). Frataxin levels in patient buccal
cells decreased with increasing repeat number, but
increased with age accounting for GAA repeat length. For
whole blood samples, R2 values were higher, as frataxin
levels correlated with GAA repeat length on the shorter
allele (R2 = 0.44, P < 0.001) and with the average age of
collection from patients (R2 = 0.24, P < 0.001) (Fig. 2C
and D). Multiple regression with both of these variables
demonstrated that both age (regression coefficient = 0.38  0.07, P < 0.001) and GAA repeat length
(regression coefficient = 0.043  0.004, P < 0.001) independently predicted frataxin levels in whole blood
(R2 = 0.49, P < 0.001). In contrast, age correlated poorly
with frataxin levels from buccal cells or blood in control
individuals (n = 120) and in FRDA carriers (n = 306)
(r < 0.12 for both tissues in both control and carrier
groups).
The GAA repeat in FRDA may display somatic variability that mediates the tissue selectivity of FRDA23; thus the
ratio of buccal and whole blood frataxin measurements
was also analyzed. While the mean ratio was 1.00, the
buccal to blood ratio correlated with the repeat length of
the shorter allele (R2 = 0.0703, P < 0.001) and the age at
collection (R2 = 0.0173, P = 0.034) (Fig. 3). But only
GAA repeat length predicted the ratio in multivariate
models (regression coefficient = 0.00082  0.00027; P =
0.003; R2 = 0.073).

Prediction of clinical status by frataxin
levels
We next sought to ascertain whether buccal cell or whole
blood levels more closely reflected neurological status. In
linear regression models of quantitative neurological
scores (FARS score, and the performance measure composites Z2 and Z3) accounting for age and sex, blood frataxin values predicted scores with higher R2 values than
buccal cells, although both were highly significant
(Table 2). In addition, the regression coefficient, indicating the slope of the relationship between FARS score and
frataxin levels, was larger for blood frataxin values compared with buccal values (blood regression coefficient = 0.549  0.061; buccal regression coefficient
= 0.318  0.073). This shows that the change in FARS
score associated with a given change in frataxin level is
greater for blood.
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Figure 1. Repeated-measures analysis of frataxin in blood and buccal cells. The change in frataxin levels between samples (ordinate, expressed as
a percentage of mean control value from unaffected individuals) was evaluated as a function of time between samples (abscissa; A and B) and
initial sample value (abscissa, expressed as a percentage of mean control value from unaffected individuals; C and D) in buccal cells (A and C) and
whole blood (B and D). There was essentially no relationship between the difference between the first and second measurements of frataxin
levels and the time difference between those two samples. Although the relationship was statistically significant in buccal cells, the R2 value was
very low and the slope of the association revealed a change in frataxin value of less than 1% per year. In contrast there was an inverse
relationship between the initial frataxin value and the change in value, consistent with regression to the mean as the reason for the mean
decrease in frataxin level with serial measurement in both blood and buccal swabs. N = 143 for buccal swabs, n = 137 for blood.

Frataxin levels in subjects with point
mutations, deletions, and unidentified
mutations
Frataxin levels were then analyzed in compound heterozygotes for GAA expansions in conjunction with point
mutations and deletions, as well as in a few FRDA subjects with unknown mutations. We previously reported
subjects with only a single disease-causing mutation and
phenotypes exactly matching that of FRDA, who had disease-level frataxin levels in buccal swabs.7 One further
such individual in the subjects was identified here.
For analysis of frataxin levels in subjects with point
mutations, one can conceptually group the subjects with
point mutations into those with G130V (a common

missense mutation with a milder atypical phenotype)3,4,24;
those carrying mutation of I154, R165, or W155 (which
alter iron binding properties of frataxin)25,26; missense
mutations in the core of the protein (e.g., L106S), which
are predicted to lead to folding abnormalities and yield
essentially no protein27; and nonsense, start codon, and
splice site mutations, which also should lead to no protein. In compound heterozygotes for a GAA expansion
and a point mutation or deletion, frataxin levels were
plotted against the length of their single GAA repeat in
both buccal cells and whole blood (Fig. 4A and B) and
the best-fit line from Figure 1A or C (frataxin levels in
buccal cells or blood for subjects homozygous for GAA
repeat expansions) was overlaid on the point mutation
data. In general, compound heterozygotes had frataxin

ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

835

Frataxin in Peripheral Tissues

M. Lazaropoulos et al.

Figure 2. Relationship between frataxin levels and disease features. Buccal cell (A and B) and blood (C and D) frataxin levels (ordinate, expressed
as a percentage of mean control value from unaffected individuals) were assessed in relationship to guanine–adenine–adenine (GAA) repeat
length and age (abscissa). Frataxin levels in both tissues correlated inversely with GAA repeat length and directly with age. N = 350 for (A), 321
for (B), 405 for (C), and 350 for (D).

levels in buccal cells that were lower than expected based
on their single GAA repeat size when compared to subjects with 2 GAA repeat expansions. This is most readily
interpreted as showing that point mutations make less
immunoreactive frataxin protein than what is expected
from the longer GAA repeat in 2 GAA repeat patients.
This was true, albeit less so, for the most common point
mutation, G130V. Levels of G130V frataxin in fibroblasts
were also lower than those observed with longer GAA
repeat lengths or shorter GAA repeat lengths, consistent
with this mutation producing lower levels of frataxin
(Fig. 4C). There were variations in frataxin levels between
specific groups of point mutations. Individuals heterozygous for mutations associated with dysfunctional frataxin
had higher levels, particularly those with R165C mutations, suggesting a preservation of immunoreactive frataxin. Although there was a single patient of each
mutation type in this group, the R165C (FRDA onset at
age eight, blind by age 18)5 and W155R (onset at age

836

four, death by age 18) subjects had frataxin levels far
greater than that expected based on their age of onset
and clinical severity.5
Previous studies suggested that specific mutations
(G130V, I154F) might be processed differently by mitochondrial processing peptidase, thus affecting their ability
to enter mitochondria.24 To assess this potential mechanism for the lower levels of selected point mutations,
mutant frataxin constructs carrying G130V, I154F, or
R165C were co-transfected with mito-GFP (as a mitochondrial marker) into HEK cells, and the distribution of
frataxin was compared to that in cells transfected with
wild type (Fig. 5). HEK cells transfected with wild-type
frataxin or frataxin carrying the R165C point mutation
had immunoreactive frataxin localized to mitochondria,
while HEK cells transfected with frataxin carrying the
G130V or I154F point mutation had no immunoreactive
frataxin overlapping with mitoGFP (Fig. 4C). This shows
that the retained levels of R165C frataxin are intrinsic to
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Figure 3. Relationship between ratio of buccal to whole blood
frataxin levels and disease features. The ratio of buccal to blood
frataxin level (ordinate) correlates with the short guanine–adenine–
adenine (GAA) length (abscissa) (P < 0.001). Longer GAA repeats are
associated with a high buccal/blood ratio. N = 230 for ratio.

the expression or stability of this mutant, and that the
lower levels observed of G130V and I154F may reflect
altered entry into the mitochondria as proposed.24
In addition, there were substantial discrepancies in
frataxin levels between blood and buccal cells in multiple subjects with point mutations and a single GAA
repeat (not shown). These individuals had blood frataxin levels that were in the expected range for carriers
or controls, while having buccal cell frataxin levels in
the lower portion of the patient range. While the buccal to blood ratio varied among most subjects slightly,
only five individuals had ratios of less than 0.10. Two
of these individuals carried truncation mutations in the

first 5 amino acids (c.2delT and c.11-12delTC). A third
subject who carried a c.2delT mutation in conjunction
with a pathologic but short (90) GAA repeat had disease levels in buccal cell (22%) with high control levels
(157%) in blood. To understand this, we analyzed the
distribution of frataxin in blood in more detail in one
subject with the c.2delT mutation (subject PA 002 in
reference 7). The proband had very low levels of frataxin in buccal cells (4.5% of control), consistent with
his clinical phenotype of FRDA, but higher amounts of
frataxin in whole blood (62.8% of control). To determine the source of the frataxin in blood, whole blood
was fractionated from this subject and his father (who
also carries the c.2delT mutation), and frataxin was
measured from buccal cells, whole blood, platelets, and
the RBC pellet (Fig. 6A). The RBC pellet, which contains low levels of mitochondria but the highest absolute amounts of frataxin,14 was responsible for the
relatively elevated frataxin level seen in whole blood in
the proband and for an elevated amount of frataxin in
blood in his c.2delT carrier father. This suggests that
this start codon mutation in FXN leads to retained
immunoreactive frataxin in RBC through an unknown
mechanism. Fractionated blood from a subject with a
frameshift mutation at amino acid 34 (c.100delG) and
in subjects who are homozygous for GAA repeat expansions did not show this pattern (Fig. 6B). Although
there was variability in the amount of frataxin in different fractions in blood in the c.100delG subject, the
variability was less than in the subject heterozygous for
a c.2delT mutation.
To explain these discrepancies, the size of frataxin in
buccal cells and in blood was determined. In both sample
types, frataxin was found at 15 kDa in controls and in
the patient with the c.2delT mutation (Fig. 6C). This
shows that the frataxin in whole blood in subjects with
the c.2delT mutation is a size consistent with mature
frataxin.

Table 2. Relation of frataxin levels and disease features in linear regression models.
Blood

Buccal cells

Parameter

Z21

Z32

FARS

Z2 1

Z32

FARS

Age
Sex
Frataxin level
Overall model R2 (P value)

<0.0001
0.83
<0.0001
0.23 (<0.0001)

<0.0001
0.78
0.0016
0.093 (<0.0001)

<0.0001
0.62
<0.0001
0.24 (<0.0001)

<0.0001
0.90
0.029
0.11 (<0.0001)

<0.0001
0.87
0.77
0.06 (0.0009)

<0.0001
0.96
<0.0001
0.10 (<0.0001)

P values are shown for the relationship of age, sex, and frataxin level with the outcome measures Z2, Z3 and FARS score in linear regression models. FARS, Friedreich Ataxia Rating Scale.
1
Z2 is defined as the sum of the z scores of the reciprocal of the nine-hole peg test and the reciprocal of the timed 25-foot walk.
2
Z3 is defined as the sum of the z scores of the reciprocal of the nine-hole peg test, the reciprocal of the timed 25-foot walk, and the
low-contrast letter acuity vision test.
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Discussion

Figure 4. Frataxin levels in subjects with point mutations. Frataxin
levels in buccal cells (ordinate, expressed as a percentage of mean
control value from unaffected individuals) (A) and blood (B) were
plotted in patients with point mutations against their expanded triplet
repeat length (abscissa). Results from individual patients (pFRDA) are
shown and labeled with the specific point mutation (A = G130V;
B = L106S; C = I154F; D = W155R; E = R165C; F = 165 + 5 G>C, a
splice site mutation). The line is the best fit line of frataxin level versus
shorter GAA repeat length for patients carrying 2 GAA repeat
expansions (cFRDA). These graphs thus present whether a point
mutation generates more frataxin than the average shorter GAA
repeat length in subjects with 2 GAA repeats. Almost all point
mutation patients fall beneath the best fit line in buccal cells, showing
that such point mutations make less frataxin than the shorter GAA
repeat. The exceptions were subjects with G130V mutations, which
approached the line, and mutations such as R165C, in which levels
were greater than those displayed by the line. For simplicity, an
individual carrying a short GAA repeat length (90) and a c.2delT
mutation with highly discrepant levels between buccal cells (22% of
control) and blood (157% of control) is not displayed, nor are two
individuals with FARA carrying a single point mutation (L156P or
c.2delT) and no identified GAA repeats (reference 7) (C). In
fibroblasts, G130V patients had levels less than those of both a short
GAA repeat patient and a long GAA repeat patient. FRDA, Friedreich
ataxia; GAA, guanine–adenine–adenine.
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In the present analysis we expanded upon our previous
studies using repeated measurements of frataxin to define
the relationship of frataxin levels with disease features
and genetic status.7 In peripheral tissues, frataxin levels
are stable over the short term but may slowly increase
over a lifetime based on statistical models. While both
buccal cell and whole blood frataxin levels are predicted
by age and GAA repeat length, the predictions are more
robust using blood values, and blood values are more closely associated with neurological severity. In addition, frataxin measurements in compound heterozygotes for a
single expanded GAA repeat and a point mutation
depend on the exact mutation, with most mutations
leading to decreased levels, others retaining frataxin
immunoreactivity, and some leading to tissue-dependent
discrepancies. All of these issues must be considered in
therapeutic trials using measurement of frataxin in
peripheral tissues.
Repeated measurements of frataxin showed that frataxin in peripheral tissues stays constant over short periods of time, but linear regression models from cross
sectional data predict a small increase in frataxin with
age. These results do not conflict as the predicted increase
(~0.2–0.4% of control per year based on the regression
coefficients) is smaller than the variability of the assay.
Biologically, the increase could reflect several phenomena.
Over many years, individuals may select for cells with
shorter GAA repeats and thus higher frataxin levels. In
addition, it has been proposed that the GAA repeat length
changes, increasing in affected tissue (such as heart and
brain) and decreasing in unaffected tissue (such as
blood), over time.23 Another possible explanation is an
age-dependent change in the extraction of frataxin from
cells. Still, changes in frataxin over the course of a lifetime
should be sufficiently small that they would not obscure
meaningful effects of therapeutic intervention.
In this study, while frataxin levels from both buccal
cells and blood were associated with the biological variables of age, GAA length, and FARS scores, the associations were more robust with levels from blood. Blood
sampling is more reproducible than sampling of buccal
cells, perhaps leading to better statistical relationships.
However, the slope of the relationship between GAA
repeat length and frataxin level is also smaller in buccal
cells than in blood, suggesting that there may be true differences in frataxin regulation between the tissues. There
is consequently a difference in the ratio of frataxin in
buccal cells to blood that changes with GAA repeat
length. These data must be interpreted in the context of
two of the paradoxes of frataxin levels in FRDA, namely
that frataxin levels in unaffected tissues overlap between
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Figure 5. Localization of point mutation frataxin in transfected cells. HEK cells were transfected with mitoGFP (green) in conjunction with
wildtype (A), G130V (B), R165C (C), or I154F (D) frataxin (all detected with red). G130V and I154F frataxin failed to colocalize with mitoGFP, a
marker of mitochondria, as shown by the separate red and green colors. In contrast, wild-type and R165C frataxin (A and C) colocalize with
mitoGFP as shown by the yellow color. This shows that wild-type and R165C readily enter mitochondria while G130V and I154F are relatively
excluded. Scale bars as shown.

FRDA, carriers and controls, and that the levels in FRDA
patients are higher than usually observed in recessive metabolic diseases. As the levels in buccal cells are slightly
lower in FRDA patients (more consistent with a diseased
phenotype or an affected tissue), buccal cell measurements might be more relevant for studies of therapeutic
intervention. This is suggested by a recent study of interferon-c in which changes in buccal cells appeared to be
more readily identified than in blood.15 Nevertheless, the
present results emphasize the need for interpretation of
changes in frataxin levels in the context of the baseline
relationships with disease-related variables.

Our data also address potential mechanisms involved
in the pathogenesis of FRDA by point mutations. In general, most point mutations probably give rise to no functional frataxin, and in many patients are associated with a
more severe phenotype. In the present cohort of compound heterozygous patients, this is generally true, particularly for truncating mutations, protein core mutations,
and splice site mutations. In contrast, patients with
R165C and W155R, non-core mutations with frataxin that
functions abnormally, had retained frataxin levels relative
to their disease severity.7,18 Thus for these mutations, the
frataxin level does not match the severe phenotype.
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Figure 6. Relative levels of frataxin in blood of FRDA patients with selected point mutations. As three patients with protein truncating mutations
in the first few amino acids had extremely low ratios of frataxin in buccal cells to blood, we addressed the localization in one such individual in
greater detail (A). In this subject, frataxin levels were extremely low in buccal cells, while in the carrier range in blood. His father, who carried the
start codon mutation c.2delT, had a similar pattern, being in the carrier range in buccal cells and in the control range in blood. When blood was
fractionated, the high level in blood in the FRDA patient and the father reflected the RBC component. His mother, who did not carry this
mutation, had carrier levels in all fractions. (B) This pattern of high levels in RBC was not found in subjects with 2 GAA repeats or in a subject
with a frameshift mutation at amino acid 34 (c.100delG). (C) We assessed the molecular weight (MW) of frataxin in these subjects to insure that
the atypical levels did to reflect processing issues. Frataxin had the same MW in buccal cells and blood in control individuals, c.100delG subject,
and the subject with the start codon mutation (c.2delT). FRDA, Friedreich ataxia; RBC, red blood cell; GAA, guanine–adenine–adenine.

In addition, levels in patients heterozygous for G130V
or I154F mutations were discrepant with the milder phenotypes usually seen with these mutations. Levels associated with G130V were depressed compared to the best fit
line for subjects homozygous for two GAA repeats and
were also decreased in fibroblasts. In addition, in transfected HEK cells, G130V and I154F frataxin fail to colocalize
with mitoGFP, showing that they enter the mitochondrion
poorly (as suggested previously using model reporter constructs).24 This accounts for the low levels of the G130V
mutant in patients, but the pathogenicity of I154F is more
complicated. This mutation also may be less functional
and may lie in the core of the protein, suggesting multiple
mechanisms for causing disease.24,25,27 While the exact
functionality of G130V is unclear, the present data implicate loss of protein for its pathogenicity. However, this
does not explain the atypical phenotype of patients carrying this mutation. Such individuals usually have a mild
phenotype characterized by atypical spasticity and a relative absence of arm, speech and cardiac dysfunction. This
would not be readily explained by a uniform loss of
frataxin, and implies the presence of unidentified cellselective features of the pathophysiology of G130V.
Another explanation for the paradoxically mild phenotype
relies on the proposed progressive somatic expansion of
the GAA repeats in FRDA.23 If GAA repeats expand as
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hypothesized in affected (e.g., brain) but not unaffected
(blood, buccal cell) tissue, then over time the level of frataxin in affected tissues would fall in individuals with GAA
repeat-mediated pathology, but not in individuals with
G130V mutations. This would give rise to paradoxically
elevated levels in blood of individuals homozygous for
GAA repeat expansions compared with compound heterozygotes for G130V, as observed here.
There also appears to be a cell-selective preservation of
immunoreactive frataxin in RBC in some subjects, particularly those heterozygous for nonsense mutations in the first
few amino acids in the protein. This occurred in both carriers and patients with the start codon mutation and was also
found in a subject with a frameshift mutation at amino
acid four (which predicts synthesis of a protein of only
three correct amino acids followed by an extended frameshifted peptide). It occurred to a lesser extent in a patient
with a frameshift mutation at amino acid 34 (c.100delG),
leading to an abnormal frataxin containing only 75 amino
acids (Fig. 6). The reason for the higher levels of frataxin
in RBC is unclear, particularly since the size of the frataxin
in RBCs matches that in other cell types. This could reflect
existence of a distinct RBC-selective splice variant, but evidence for such differential splicing is limited.28 Alternatively, as proposed by Zhu et al., such mutations may
allow utilization of an alternate start codon that results in a
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truncated form of frataxin missing its N-terminal mitochondrial-targeting sequence.29 In RBCs, such a form
might be more readily retained due to the relatively incomplete cell biological machinery of erythrocytes, including
ubiquitin-based degradation systems.30 This alternative
start codon is found at amino acid 76, essentially identical
to the processing site of mature frataxin; thus, the molecular weight of mature mitochondrial frataxin and frataxin
derived from this alternative start codon would be almost
indistinguishable. As the frataxin made from an alternative
start site would not be localized to mitochondria, it serves
as a reminder of the difference between functional and
immunoreactive frataxin, and the variability that can occur
in cell selective processing events. However, such an explanation cannot be used to explain the relatively elevated levels of frataxin in the blood of subjects with deletions or
other point mutations. Consequently, multiple mechanisms may contribute to the elevated levels in blood in
some patients. Thus, the present work demonstrates the
complexity of peripheral frataxin levels in FRDA, and the
need for consideration of multiple factors in interpretation
of the results of clinical intervention studies.
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